ATE484596T1 - Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom - Google Patents

Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom

Info

Publication number
ATE484596T1
ATE484596T1 AT04798619T AT04798619T ATE484596T1 AT E484596 T1 ATE484596 T1 AT E484596T1 AT 04798619 T AT04798619 T AT 04798619T AT 04798619 T AT04798619 T AT 04798619T AT E484596 T1 ATE484596 T1 AT E484596T1
Authority
AT
Austria
Prior art keywords
herpes simplex
simplex virus
cell carcinoma
squamous cell
treatment
Prior art date
Application number
AT04798619T
Other languages
English (en)
Inventor
Susanne Moira Brown
Paul Dunn
Bhuvanesh Singh
Ian Ganly
Original Assignee
Crusade Lab Ltd
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crusade Lab Ltd, Sloan Kettering Inst Cancer filed Critical Crusade Lab Ltd
Priority claimed from PCT/GB2004/004908 external-priority patent/WO2005049846A2/en
Application granted granted Critical
Publication of ATE484596T1 publication Critical patent/ATE484596T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04798619T 2003-11-17 2004-11-17 Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom ATE484596T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0326798.6A GB0326798D0 (en) 2003-11-17 2003-11-17 Methods for generating mutant virus
US54130804P 2004-02-03 2004-02-03
PCT/GB2004/004908 WO2005049846A2 (en) 2003-11-17 2004-11-17 Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer

Publications (1)

Publication Number Publication Date
ATE484596T1 true ATE484596T1 (de) 2010-10-15

Family

ID=29763982

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04798569T ATE433493T1 (de) 2003-11-17 2004-11-17 Für eine heterologe nitroreduktase kodierender onkolytischer herpes simplex virus
AT04798619T ATE484596T1 (de) 2003-11-17 2004-11-17 Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04798569T ATE433493T1 (de) 2003-11-17 2004-11-17 Für eine heterologe nitroreduktase kodierender onkolytischer herpes simplex virus

Country Status (7)

Country Link
US (3) US7498161B2 (de)
EP (3) EP1692294A2 (de)
JP (1) JP2007511215A (de)
AT (2) ATE433493T1 (de)
DE (2) DE602004021496D1 (de)
GB (1) GB0326798D0 (de)
WO (2) WO2005049845A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
EP1694852B1 (de) 2003-11-17 2010-10-13 Crusade Laboratories Limited Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom
WO2007026146A1 (en) * 2005-08-30 2007-03-08 Crusade Laboratories Limited Treatment using herpes simplex virus
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
GB0409596D0 (en) * 2004-04-29 2004-06-02 Crusade Lab Ltd Novel herpes simplex viruses and uses thereof
US20120301506A1 (en) * 2010-11-23 2012-11-29 Xiaoliu Zhang Oncolytic Virus as an Inducer for Innate Antitumor Immunity
US8163292B2 (en) 2007-02-16 2012-04-24 Virttu Biologics Limited Herpes simplex viruses and methods of viral replication
US20090081639A1 (en) * 2007-05-31 2009-03-26 Phil Hill Assay for sensitivity to chemotherapeutic agents
GB0714578D0 (en) * 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses
US8334097B2 (en) * 2009-05-01 2012-12-18 Vivebio, Llc Method of pooling and/or concentrating biological specimens for analysis
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
EP2593796A4 (de) * 2010-07-16 2016-07-27 Auckland Uniservices Ltd Bakterielle nitroreduktase-enzyme und verfahren dafür
US9447156B2 (en) 2011-05-17 2016-09-20 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
WO2013052915A2 (en) 2011-10-05 2013-04-11 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
US20130280170A1 (en) 2012-04-20 2013-10-24 Aladar A. Szalay Imaging methods for oncolytic virus therapy
EP2662117A1 (de) 2012-05-11 2013-11-13 Virttu Biologics Limited Herpes Simplex Virus zur Behandlung von Leberkrebs
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
CA3126536C (en) 2014-10-14 2023-07-25 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
KR102536850B1 (ko) 2016-04-15 2023-05-26 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
KR20190006495A (ko) 2016-04-15 2019-01-18 알파인 이뮨 사이언시즈, 인코포레이티드 Cd80 변이체 면역조절 단백질 및 그의 용도
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022946A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
SG11201903407XA (en) 2016-10-20 2019-05-30 Alpine Immune Sciences Inc Secretable variant immunomodulatory proteins and engineered cell therapy
CN110869052A (zh) 2016-12-23 2020-03-06 维图生物制剂公司 癌症的治疗
WO2018148462A1 (en) 2017-02-09 2018-08-16 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and compositions and methods thereof
WO2018170023A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
CA3054068A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
KR20240039221A (ko) 2017-03-16 2024-03-26 알파인 이뮨 사이언시즈, 인코포레이티드 Pd-l1 리간드 변이체 면역조절 단백질 및 그의 용도
MA50404A (fr) 2017-10-18 2020-08-26 Alpine Immune Sciences Inc Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées
CN110117577B (zh) * 2018-02-05 2023-10-24 中国科学院武汉物理与数学研究所 低毒单纯疱疹病毒***及其构建方法和应用
CA3098572A1 (en) * 2018-05-01 2019-11-07 Albert Einstein College Of Medicine Hsv-2-delta-gd vaccines and methods for their production and use
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
CA3177467A1 (en) 2018-06-04 2019-12-12 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
US20210363219A1 (en) 2018-06-15 2021-11-25 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
EP3876951A1 (de) 2018-11-06 2021-09-15 Calidi Biotherapeutics, Inc. Verbesserte systeme für zellvermittelte onkolytische virustherapie
WO2020107002A2 (en) 2018-11-21 2020-05-28 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
CA3120868A1 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
EP3931210A1 (de) 2019-02-27 2022-01-05 Actym Therapeutics, Inc. Zur besiedlung von tumoren, tumorresidenten immunzellen und der mikroumgebung des tumors entwickelte immunstimulatorische bakterien
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
EP4139439A1 (de) 2020-04-22 2023-03-01 Indapta Therapeutics, Inc. Zusammensetzungen natürlicher killerzellen (nk) und verfahren zur erzeugung davon
TW202241479A (zh) 2020-12-30 2022-11-01 美商安迅生物製藥公司 遞送外來抗原之溶瘤病毒及表現靶向外來抗原之嵌合受體之經工程化免疫細胞之組合療法
LT7046B (lt) 2022-04-15 2024-02-12 Vilniaus Universitetas Hidrolazės ir jų panaudojimas

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965138A (en) 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
DE68912441T2 (de) 1988-06-24 1994-05-11 British Tech Group Nichtessentielle Geflügelpockenvirus-Regionen.
GB9102126D0 (en) 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
ES2212795T3 (es) 1991-08-26 2004-08-01 Baxter Healthcare S.A. Virus de la viruela de las aves de corral recombinante.
AU681337B2 (en) * 1991-10-23 1997-08-28 Cancer Research Campaign Technology Limited Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
CA2167706A1 (en) 1993-07-27 1995-02-09 Nigel Fraser Modified dna virus vectors and uses therefor
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
EP0753581A1 (de) 1995-07-10 1997-01-15 Immuno Ag Verbesserte rekombinante eukaryotische zytoplasmatische Viren, Methode ihrer Herstellung und ihrer Verwendung als Impfstoffe
ZA966287B (en) 1995-07-27 1998-03-09 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines.
WO1997014808A2 (en) 1995-10-19 1997-04-24 St. Jude Children's Research Hospital Herpesvirus vectors and their uses
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9801930D0 (en) * 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
US5922576A (en) * 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
CA2327506A1 (en) * 1998-04-30 1999-11-04 The General Hospital Corporation Combination viral-based and gene-based therapy of tumors
EP1153136A2 (de) * 1998-12-09 2001-11-14 The General Hospital Corporation Verbessertes verpacken von hsv-amplikons und herstellung von rekombinanten viralen vektoren
ES2233349T3 (es) * 1999-08-31 2005-06-16 The General Hospital Corporation Reordenacion por promotores especificos para una celula y/o especificos para un tumor de la expresion del gen gamma 34,5 herpetico.
EP1111061A1 (de) * 1999-12-20 2001-06-27 Universite Libre De Bruxelles Vektor mit doppelter Selektion
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
EP1568779A1 (de) * 2000-01-21 2005-08-31 BioVex Limited hsv-stämme für die onkolytische behandlung von krebs
CA2452653A1 (en) * 2001-07-17 2003-01-30 Anne Josephine Milner Silencing of gene expression by sirna
NZ531413A (en) 2001-08-21 2006-01-27 Innovata Plc Improved nitroreductase enzymes
US7348418B2 (en) 2002-02-08 2008-03-25 Memorial Sloan-Kettering Cancer Center Carcinoma-related genes and polypeptides and methods of use thereof
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
JP2005519091A (ja) * 2002-03-01 2005-06-30 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の再発及び転移の予防
US7288529B2 (en) * 2003-04-24 2007-10-30 New York University ALK protein tyrosine kinase, cells and methods embodying and using same

Also Published As

Publication number Publication date
DE602004029608D1 (de) 2010-11-25
WO2005049845A2 (en) 2005-06-02
US20090208460A1 (en) 2009-08-20
US7498161B2 (en) 2009-03-03
WO2005049844A3 (en) 2005-10-20
WO2005049844A2 (en) 2005-06-02
GB0326798D0 (en) 2003-12-24
EP1685254B1 (de) 2009-06-10
ATE433493T1 (de) 2009-06-15
EP1685254A2 (de) 2006-08-02
EP2281897A3 (de) 2011-11-30
EP1692294A2 (de) 2006-08-23
US20070110720A1 (en) 2007-05-17
US20070098689A1 (en) 2007-05-03
WO2005049845A3 (en) 2005-10-27
WO2005049845A9 (en) 2006-08-17
DE602004021496D1 (de) 2009-07-23
EP2281897A2 (de) 2011-02-09
JP2007511215A (ja) 2007-05-10

Similar Documents

Publication Publication Date Title
ATE484596T1 (de) Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom
WO2005049846A3 (en) Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
WO2004024872A3 (en) Method for expression of small antiviral rna molecules within a cell
CY1122342T1 (el) Ειδικοι ως προς την ακολουθια rna μεσολαβητες της παρεμβολης rna
AU2002327412A1 (en) Methods and compositions relating to improved lentiviral vector production systems
ATE513910T1 (de) Methoden zur gensuppression mithilfe von rnai verstärkenden faktoren
ATE513843T1 (de) Abstellen von genen in vivo durch chemischmodifizierte und stabile sirna
DK1554301T3 (da) Dengue-vaccine med en fælles udeladelse af 30 nukleotider i Dengue-typerne 1's og 2's3'UTR
HUP0300570A2 (hu) Cestrum sárga levélfodrosodás vírus promóterek
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
DK2230304T3 (da) IRNA-modulering af RSV og terapeutiske anvendelser deraf
TR200100104T2 (tr) Bitkilerde transgenlerin sentezlenmesi için yöntemler ve bileşimler
WO2004058940A3 (en) Sirna-mediated gene silencing
ATE510920T1 (de) Dna-sequenzen zur regulation der transkription
DK0421376T3 (da) Multifunktionelt RNA med selvprocesseringsaktivitet, dets fremstilling og anvendelse
ATE469984T1 (de) Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
ATE527356T1 (de) Replikationskompetente viren für genabschaltung von virusinaktivierung faktor
ATE310085T1 (de) Cyclin-e2 proteine und dafür kodierende gene
WO2003104470A3 (en) LET US RETURN FOR GENE TARGETING
ATE294866T1 (de) Zellen, die virus-resistent und von viren infizierbar sind
ATE365807T1 (de) Hepatitis b virus vektoren für gentherapie
MXPA02003422A (es) Alteracion de la expresion de genes con adnss producido in vivo.
DE69515652D1 (de) Verwendung von dna oligomeren zur hemmung von hiv durch reduktion ribosomaler leserasterverschichtung
DE69936141D1 (de) Verwendung von dna-pk
ATE301721T1 (de) In vivo herstellung von replicativen molekülen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties